Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACC-001 + QS-21 in Mild to Moderate Alzheimer's Disease
NCT01284387Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2011
- Primary completion
- Jan 2014
- Modality
- Antibody Conjugates, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of vanutide cridificar in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Started Jan 2011; status: completed.
02
Drugs
vanutide cridificar
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01284387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01284387.